Columbia University, New York (NY) USA
Preliminary results from the dose-escalation part of Phase I study in patients with relapsed/refractory cutaneous T-cell lymphomas will be presented by Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital, Paris, at the Third World Congress of Cutaneous Lymphomas “3WCCL” (October 26-28, 2016, in New-York, USA).
The presentation will be made available on the Company’s website, in the Product Pipeline - IPH4102 section after the session.
About the presentation:
- Title: “First-in-Human, open label, multicenter phase I study of IPH4102, first-in-class humanized anti-KIR3DL2 mAb, in relapsed/refractory CTCL: preliminary safety and clinical activity results”
- Scientific Session O. Therapeutics 3a: Endpoints & Clinical Trials
- Date: October 28, 2016
- Presentaton Time: 13:30 – 14:45 EST
- Presenter: Pr. Martine Bagot, Head of the Dermatology Department, Saint-Louis Hospital, Paris
- Location: Roone Arledge Auditorium - Alfred Lerner Hall at Columbia University – New York
Date